Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System.

Applied health economics and health policy - 1 Oct 2017

Kim Dong-Jin, Kim Ho-Sook, Oh Minkyung, Kim Eun-Young, Shin Jae-Gook

Abstract excerpt

BACKGROUND: Although studies assessing the cost effectiveness of genotype-guided warfarin dosing for the management of atrial fibrillation, deep vein thrombosis, and pulmonary embolism have been reported, no publications have addressed genotype-guided warfarin therapy in mechanical heart valve replacement (MHVR) patients or genotype-guided warfarin therapy under the fee-for-service (FFS) insurance system....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anticoagulants

Share to Atrial Fibrillation

Share to Cost-Benefit Analysis

Share to Genetic Predisposition to Disease

Share to Republic of Korea

Share to Warfarin

Source

Identifiers

PMID: 28247199
DOI: 10.1007/s40258-017-0317-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System.PMID 28247199Read ↗

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.Semantic proximity Read ↗

Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.Semantic proximity Read ↗

Genotype-guided warfarin dosing may benefit patients with mechanical aortic valve replacements: randomized controlled study.Semantic proximity Read ↗

Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis.Semantic proximity Read ↗

Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis.Semantic proximity Read ↗

Pharmacist-Led Genotype-Guided Warfarin Therapy in Valve Replacement: An Observation Cohort Study.Semantic proximity Read ↗

Genotype-Guided Warfarin Dosing in Patients With Mechanical Valves: A Randomized Controlled Trial.Semantic proximity Read ↗

Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.Semantic proximity Read ↗

Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.Semantic proximity Read ↗

Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.Semantic proximity Read ↗

Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin.Semantic proximity Read ↗

Meta-Analysis of Genotype-Guided Versus Standard Dosing of Vitamin K Antagonists.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.